Healthcare -
Biotechnology - NASDAQ - US
$ 1.62
0.621 %
$ 74.1 M
Market Cap
-1.72
P/E
1. INTRINSIC VALUE
Balance Sheet
PDS Biotechnology Corporation
| Current Assets | 45.1 M |
| Cash & Short-Term Investments | 41.7 M |
| Receivables | 0 |
| Other Current Assets | 3.36 M |
| Non-Current Assets | 304 K |
| Long-Term Investments | 0 |
| PP&E | 304 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 17.1 M |
| Accounts Payable | 1.68 M |
| Short-Term Debt | 12.6 M |
| Other Current Liabilities | 2.84 M |
| Non-Current Liabilities | 9.27 M |
| Long-Term Debt | 9.27 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
PDS Biotechnology Corporation
| Revenue | 0 |
| Cost Of Revenue | 59.8 K |
| Gross Profit | -59.8 K |
| Operating Expenses | 36.3 M |
| Operating Income | -36.3 M |
| Other Expenses | 1.29 M |
| Net Income | -37.6 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
PDS Biotechnology Corporation
| Net Income | -37.6 M |
| Depreciation & Amortization | 21.1 K |
| Capital Expenditures | -29 K |
| Stock-Based Compensation | 6.85 M |
| Change in Working Capital | -5.75 M |
| Others | 1.01 M |
| Free Cash Flow | -35.1 M |
Wall Street Analysts Price Targets
PDS Biotechnology Corporation
PDSB has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
PDSB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
PDS Biotechnology Corporation
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
96.1 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC
Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe
globenewswire.com
- 2 weeks ago
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
PDS Biotech announced the publication of three Versamune® HPV abstracts that were presented during the Head and Neck Cancer Poster Session at ASCO 2025.
globenewswire.com
- 3 weeks ago
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Phase 2: Versamune ® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC
globenewswire.com
- 1 month ago
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase
PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will participate in a fireside chat during the Alliance Global Partners (“A.G.P.”) Virtual Annual Healthcare Company Showcase, taking place May 21, 2025.
globenewswire.com
- 1 month ago
EMV Capital portfolio company PDS Biotech advances cancer trial
PDS Biotechnology Corporation (NASDAQ:PDSB), a US cancer immunotherapy firm backed by EMV Capital (AIM:EMVC), has begun site activations for its phase III trial of Versamune HPV in patients with head and neck cancers linked to HPV16. The trial, which will enrol around 350 patients, is supported by the US Food and Drug Administration Fast Track designation and includes interim data readouts.
proactiveinvestors.co.uk
- 1 month ago
PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Frank Bedu-Addo - CEO Lars Boesgaard - CFO Kirk Shepard - Chief Medical Officer Mike Moyer - IR, LifeSci Advisors Conference Call Participants Mayank Mamtani - B. Riley Securities Joseph Pantginis - H.C.
seekingalpha.com
- 1 month ago
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J.
globenewswire.com
- 1 month ago
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that on May 5, 2025, PDS Biotech granted a nonstatutory stock option to purchase 5,000 shares of common stock to an employee in its clinical department as a material inducement to such employee's employment and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech's 2019 Inducement Plan, as amended, which was adopted on June 17, 2019, and provides for the granting of equity awards to new employees of PDS Biotech.
globenewswire.com
- 1 month ago
PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the quarter ended March 31, 2025, and provide a clinical programs update on Wednesday, May 14, 2025 at 8:00 a.m.
globenewswire.com
- 1 month ago
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that three abstracts on Versamune® HPV (PDS0101) have been accepted for presentation at the 2025 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 30-June 3, 2025, in Chicago, Illinois.
globenewswire.com
- 2 months ago
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting
PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that preclinical immune response data with a novel Infectimune® based flu vaccine will be featured in a symposium on universal influenza vaccines at the American Association of Immunologists' IMMUNOLOGY2025™ Annual Meeting, taking place May 3-7, 2025, in Honolulu, Hawaii.
globenewswire.com
- 2 months ago
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that an abstract submitted by the National Cancer Institute (“NCI”) reporting clinical data on PDS01ADC, the Company's IL-12 fused antibody drug conjugate, has been accepted for presentation at the American Association for Cancer Research (“AACR”) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois.
globenewswire.com
- 2 months ago
8. Profile
Summary
PDS Biotechnology Corporation PDSB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 74.1 M
Dividend Yield
0.00%
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Contact
25B Vreeland Road, Princeton, NJ, 07932
https://www.pdsbiotech.com
IPO
Date
Sept. 30, 2015
Employees
24
Officers
Ms. Janetta Trochimiuk
Controller
Mr. Lars Robert Boesgaard M.B.A.
Principal Financial & Accounting Officer and Chief Financial Officer
Mr. Stephan Toutain M.B.A., M.S.
Chief Operating Officer
Dr. Kirk V. Shepard M.D.
Chief Medical Officer
Mr. Spencer Brown J.D.
Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer
Dr. Frank K. Bedu-Addo Ph.D.
President, Chief Executive Officer & Director
Dr. Gregory L. Conn Ph.D.
Chief Scientific Officer